Overall survival of patients with non-small cell lung cancer after surgery treatment

被引:2
作者
Loncarevic, Olivera [1 ]
Acimovic, Slobodan [1 ]
Vukovic, Jelena [1 ]
Stojisavljevic, Marko [1 ]
Maric, Nebojsa [2 ]
Loncarevic, Slobodan [3 ]
Petrovic, Marina [5 ]
Milivojevic, Ivana [6 ]
Ignjic, Gordana [7 ]
Milic, Gordana [1 ]
Mirilo, Leonida [8 ]
Rancic, Nemanja [4 ]
机构
[1] Mil Med Acad, Pulmonol Clin, Crnotravska 17, Belgrade 11000, Serbia
[2] Mil Med Acad, Clin Chest Surg, Belgrade, Serbia
[3] Mil Med Acad, Clin Maxillofacial Surg, Belgrade, Serbia
[4] Mil Med Acad, Ctr Clin Pharmacol, Belgrade, Serbia
[5] Univ Kragujevac, Fac Med Sci, Clin Ctr Kragujevac, Ctr Pulm Dis, Kragujevac, Serbia
[6] Special Hosp Lung Dis Ozren, Sokobanja, Serbia
[7] PHO Hosp Sveti Vracevi, Dept Pulmonol, Bijeljina, Bosnia & Herceg
[8] BELhosp Ctr Palliat Care & Palliat Med, Belgrade, Serbia
关键词
carcinoma; non-small-cell lung; adenocarcinoma; squamous cell carcinoma; survival; recurrence; ADJUVANT CHEMOTHERAPY; RISK-FACTORS; EARLY-STAGE; RADIOTHERAPY; RECURRENCE; THERAPY;
D O I
10.2298/VSP161226043L
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Aim. Lung cancer is one of the most common malignant tumors. About 80% of all lung cancers are non-small cell lung cancer (NSCLC). According to histopathological characteristics, the most common types of NSCLC are squamous cell carcinoma and adenocarcinoma. The aim of this study was to evaluate the overall survival rate in the NSCLC patients initially received surgery according to its histopathological type and T - primary tumor, N - regional lymph nodes, M - distant metastasis (TNM) stages which were treated with surgical treatment, and after that, according to the TNM stage, chemotherapy protocols and/or radiation therapy. Methods. This retrospective case series study included all patients with NSCLC admitted to the Military Medical Academy in Belgrade in the period 2010-2015. A total number of selected patients was 85 (27 females and 58 males). Results. Out of 41 patients with squamous cell carcinoma, 19.5% deceased. On the other hand, in the group of patients with adenocarcinoma, 43.2% out of 44 patients deceased. The average cumulative survival was statistically significantly lower in the adenocarcinoma patients in comparison to the patients with squamous cell carcinoma (1,605.2 vs. 1,304.8 days; p = 0.005). On the other hand, the average cumulative survival was statistically significantly lower in our patients in the recurrence group with adenocarcinoma in comparison to the recurrence group with squamous cell carcinoma (1,212.8 vs. 1,835.5 days; p = 0.032). Conclusion. Adenocarcinoma is more aggressive cancer in comparing to squamous cell carcinoma with lower overall survival in comparing to squamous cell carcinoma. Additional studies are needed to identify risk factors for recurrence after surgery, and to additionally explain role of tumor markers and molecular biological techniques in the progression of this kind of cancer.
引用
收藏
页码:1157 / 1164
页数:8
相关论文
共 28 条
  • [1] American Cancer Society, NONSM CELL LUNG CANC
  • [2] [Anonymous], 2004, Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs
  • [3] [Anonymous], NATL GUIDELINES GOOD
  • [4] [Anonymous], 2016, CANC FACTS FIG
  • [5] Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer
    Chuang, Jody C.
    Liang, Ying
    Wakelee, Heather A.
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (01) : 31 - +
  • [6] Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Crino, L.
    Weder, W.
    van Meerbeeck, J.
    Felip, E.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : v103 - v115
  • [7] Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer
    Durm, Greg
    Hanna, Nasser
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (01) : 71 - +
  • [8] Overall survival in non-small cell lung cancer-what is clinically meaningful?
    Fenchel, Klaus
    Sellmann, Ludger
    Dempke, Wolfram C. M.
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (01) : 115 - 119
  • [9] Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI [10.1001/jamaoncol.2016.5688, 10.1001/jamaoncol.2018.2706]
  • [10] First-Line Systemic Therapy for Non-Small Cell Lung Cancer
    Heist, Rebecca S.
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (01) : 59 - +